Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis
GR Burmester, SB Cohen, KL Winthrop, P Nash… - RMD open, 2023 - rmdopen.bmj.com
Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD) …
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD) …
Ten years after ruxolitinib approval for myelofibrosis: A review of clinical efficacy
N Pemmaraju, P Bose, R Rampal, AT Gerds… - Leukemia & …, 2023 - Taylor & Francis
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by splenomegaly,
abnormal cytokine expression, cytopenias, and progressive bone marrow fibrosis. The …
abnormal cytokine expression, cytopenias, and progressive bone marrow fibrosis. The …
Cancer risk in patients treated with the JAK inhibitor tofacitinib: systematic review and meta-analysis
C Bezzio, M Vernero, DG Ribaldone, E Alimenti… - Cancers, 2023 - mdpi.com
Simple Summary Tofacitinib is a relatively novel therapy for immune-mediated inflammatory
diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a small …
diseases, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a small …
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib
A Rampotas, L Carter-Brzezinski, TCP Somervaille… - Blood, 2024 - ashpublications.org
Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative
neoplasms behave aggressively, with adverse features and high recurrence. In our cohort …
neoplasms behave aggressively, with adverse features and high recurrence. In our cohort …
[HTML][HTML] Cutaneous Squamous Cell Carcinoma in Patients with Solid-Organ-Transplant-Associated Immunosuppression
K Khaddour, N Murakami, ES Ruiz, AW Silk - Cancers, 2024 - mdpi.com
The management of advanced cutaneous squamous cell carcinoma (CSCC) has been
revolutionized by the introduction of immunotherapy. Yet, successful treatment with …
revolutionized by the introduction of immunotherapy. Yet, successful treatment with …
Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE …
R Fleischmann, J Swierkot, SK Penn, P Durez… - RMD open, 2024 - rmdopen.bmj.com
Objectives To assess the safety and efficacy of upadacitinib versus adalimumab from
SELECT-COMPARE over 5 years. Methods Patients with rheumatoid arthritis and …
SELECT-COMPARE over 5 years. Methods Patients with rheumatoid arthritis and …
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study
A Rubbert-Roth, K Kato, B Haraoui… - Rheumatology and …, 2024 - Springer
Introduction The safety and efficacy of upadacitinib 15 mg (UPA15) through week 216 was
evaluated in patients with rheumatoid arthritis (RA) from the long-term extension (LTE) of the …
evaluated in patients with rheumatoid arthritis (RA) from the long-term extension (LTE) of the …
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
M Mansilla-Polo, D Morgado-Carrasco - Dermatology and Therapy, 2024 - Springer
Introduction Biological drugs (BD) and Janus kinase inhibitors (JAKi) have revolutionized
the treatment of diverse dermatoses. However, there are concerns regarding their safety …
the treatment of diverse dermatoses. However, there are concerns regarding their safety …
[HTML][HTML] Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models
EA Pedersen, ME Verhaegen, MK Joseph… - Frontiers in …, 2024 - ncbi.nlm.nih.gov
Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma
thought to arise via either viral (Merkel cell polyomavirus) or ultraviolet-associated pathways …
thought to arise via either viral (Merkel cell polyomavirus) or ultraviolet-associated pathways …
Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of …
GR Burmester, J Stigler, A Rubbert-Roth… - Rheumatology and …, 2024 - Springer
Introduction This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes
the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure …
the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure …